tiprankstipranks
Trending News
More News >
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
US Market

Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

Compare
830 Followers
See the Price Targets and Ratings of:

ELDN Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Eledon
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELDN Stock 12 Month Forecast

Average Price Target

$9.00
▲(230.88%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is $9.00 with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 230.88% change from the last price of $2.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.5938461538461537,4.127692307692308,4.661538461538462,5.195384615384615,5.729230769230769,6.263076923076923,6.796923076923077,7.330769230769231,7.8646153846153855,8.39846153846154,8.932307692307692,9.466153846153846,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.516923076923077,3.9738461538461536,4.430769230769231,4.887692307692308,5.344615384615384,5.8015384615384615,6.258461538461538,6.715384615384615,7.172307692307692,7.6292307692307695,8.086153846153845,8.543076923076923,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.44,3.82,4.2,4.58,4.96,5.34,5.72,6.1,6.4799999999999995,6.859999999999999,7.24,7.619999999999999,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.99,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$9.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ELDN
Yi ChenH.C. Wainwright
H.C. Wainwright
$9
Buy
230.88%
Upside
Initiated
06/18/25
Eledon Pharmaceuticals: Promising Kidney Transplant Treatment Spurs Buy Rating
Noble Financial Analyst forecast on ELDN
Robert LeBoyerNoble Financial
Noble Financial
$10
Buy
267.65%
Upside
Reiterated
05/19/25
Eledon Pharmaceuticals (ELDN) Receives a Buy from Noble Financial
Leerink Partners Analyst forecast on ELDN
Thomas SmithLeerink Partners
Leerink Partners
$8
Buy
194.12%
Upside
Reiterated
05/15/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
LifeSci Capital Analyst forecast on ELDN
Rami KatkhudaLifeSci Capital
LifeSci Capital
$9
Buy
230.88%
Upside
Reiterated
05/15/25
Eledon Pharmaceuticals: Strong Financials and Promising Trials Justify Buy Rating
Cantor Fitzgerald Analyst forecast on ELDN
Pete StavropoulosCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/15/25
Cantor Fitzgerald reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Eledon Pharamceuticals (NASDAQ: ELDN).
Guggenheim Analyst forecast on ELDN
Vamil DivanGuggenheim
Guggenheim
$9
Buy
230.88%
Upside
Reiterated
05/14/25
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)
Ladenburg Thalmann & Co. Analyst forecast on ELDN
Matthew KaplanLadenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$28$20.5
Buy
653.68%
Upside
Reiterated
11/13/24
Eledon Pharmaceuticals price target lowered to $20.50 from $28 at LadenburgEledon Pharmaceuticals price target lowered to $20.50 from $28 at Ladenburg
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ELDN
Yi ChenH.C. Wainwright
H.C. Wainwright
$9
Buy
230.88%
Upside
Initiated
06/18/25
Eledon Pharmaceuticals: Promising Kidney Transplant Treatment Spurs Buy Rating
Noble Financial Analyst forecast on ELDN
Robert LeBoyerNoble Financial
Noble Financial
$10
Buy
267.65%
Upside
Reiterated
05/19/25
Eledon Pharmaceuticals (ELDN) Receives a Buy from Noble Financial
Leerink Partners Analyst forecast on ELDN
Thomas SmithLeerink Partners
Leerink Partners
$8
Buy
194.12%
Upside
Reiterated
05/15/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
LifeSci Capital Analyst forecast on ELDN
Rami KatkhudaLifeSci Capital
LifeSci Capital
$9
Buy
230.88%
Upside
Reiterated
05/15/25
Eledon Pharmaceuticals: Strong Financials and Promising Trials Justify Buy Rating
Cantor Fitzgerald Analyst forecast on ELDN
Pete StavropoulosCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/15/25
Cantor Fitzgerald reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Eledon Pharamceuticals (NASDAQ: ELDN).
Guggenheim Analyst forecast on ELDN
Vamil DivanGuggenheim
Guggenheim
$9
Buy
230.88%
Upside
Reiterated
05/14/25
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)
Ladenburg Thalmann & Co. Analyst forecast on ELDN
Matthew KaplanLadenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$28$20.5
Buy
653.68%
Upside
Reiterated
11/13/24
Eledon Pharmaceuticals price target lowered to $20.50 from $28 at LadenburgEledon Pharmaceuticals price target lowered to $20.50 from $28 at Ladenburg
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eledon Pharmaceuticals

1 Month
xxx
Success Rate
5/10 ratings generated profit
50%
Average Return
+4.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.87% per trade.
3 Months
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+7.54%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +7.54% per trade.
1 Year
Robert LeBoyerNoble Financial
Success Rate
5/10 ratings generated profit
50%
Average Return
+9.19%
reiterated a buy rating last month
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +9.19% per trade.
2 Years
xxx
Success Rate
9/20 ratings generated profit
45%
Average Return
+3.78%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 45.00% of your transactions generating a profit, with an average return of +3.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELDN Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
May 25
Jun 25
Strong Buy
6
6
6
9
9
Buy
2
1
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
7
7
10
10
In the current month, ELDN has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ELDN average Analyst price target in the past 3 months is 9.00.
Each month's total comprises the sum of three months' worth of ratings.

ELDN Financial Forecast

ELDN Earnings Forecast

The previous quarter’s earnings for ELDN were -$0.08.
The previous quarter’s earnings for ELDN were -$0.08.
No data currently available

ELDN Sales Forecast

The previous quarter’s earnings for ELDN were $0.00.
The previous quarter’s earnings for ELDN were $0.00.

ELDN Stock Forecast FAQ

What is ELDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Eledon Pharmaceuticals’s 12-month average price target is 9.00.
    What is ELDN’s upside potential, based on the analysts’ average price target?
    Eledon Pharmaceuticals has 230.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELDN a Buy, Sell or Hold?
          Eledon Pharmaceuticals has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Eledon Pharmaceuticals’s price target?
            The average price target for Eledon Pharmaceuticals is 9.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $8.00. The average price target represents 230.88% Increase from the current price of $2.72.
              What do analysts say about Eledon Pharmaceuticals?
              Eledon Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of ELDN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis